What he needed was a "white knight." He did some poking around and came up with Winston Bartlett, then floated feelers to Bartlett's people. What if, he proposed, Bartlett acquired the Gerex Corporation for BMD and made it a for‑profit business? No more public funding (and maddening administrative meddling). The research already completed was so close to a payoff, after years and years of grinding lab work and thousands of white mice, that the deal could be considered an investment where 95 percent of the seed money had already been supplied by taxpayers.
Winston Bartlett had liked the sound of that, and Karl Van de Vliet had his white knight.
Once his financing was secure, he decided to begin by solving the problem that had dogged him at Stanford. Since there would always be a distracting public‑relations problem hounding any researcher in the United States who made use of aborted embryos, even if it was to save lives, he was determined to find a less controversial way to trick Mother Nature and garner "pluripotent" stem cells, the name given those that could give rise to virtually any tissue type.
He had. After he moved his research team into the Dorian Institute just over 4 1/2 years ago, he had perfected a way to use a human protein, an enzyme called telomerase, to make adult stem cells do most of the miracles once only thought possible with embryonic cells.
The phase‑three clinical trials over the past seven months had proved conclusively that the technique worked. Adult stem cells, when treated with the telomerase enzyme to arrest the process of cell senescence, could indeed regenerate everything from the human brain to the human heart, from Parkinson's to acute myocardial infarction.
Twenty‑three days from now, when the phase‑three clinical trials were formally scheduled to be completed, Karl Van de Vliet would have enough data for the National Institutes of Health to confirm one of the most important breakthroughs in the history of medicine.
Unfortunately, however, there was that other bit of data that he would not be sharing with the NIH. The Beta.
Thinking about that, his heart heavy, he turned back to the situation at hand.
"Emma, you're making wonderful progress," he continued on with the banter, "but don't push yourself too hard just yet."
She laughed, sending lines across her forehead. Her voice was deep and rich, sultry in its own way. "When you get as old as I am, honey, you do anything you can get away with. What am I saving it for? I just might go to Atlantic City next week and pick up a sailor."